Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients
- 24 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Human Genetics
- Vol. 140 (2), 321-331
- https://doi.org/10.1007/s00439-020-02207-6
Abstract
High-throughput sequencing has greatly contributed to precision medicine. However, challenges remain in reporting secondary findings (SFs) of germline pathogenic variants and managing the affected patients. The aim of this study was to examine the incidence of SFs in Japanese cancer patients using whole exome sequencing (WES) and to understand patient preferences regarding SF disclosure. WES was conducted for 2480 cancer patients. Genomic data were screened and classified for variants of 59 genes listed by the American College of Medical Genetics and Genomics SF v2.0 and for an additional 13 hereditary cancer-related genes. Majority of the participants (68.9%; 1709/2480) opted for disclosure of their SFs. Thirty-two pathogenic or likely pathogenic variants, including BRCA1 (7 patients), BRCA2 (4), CHEK2 (4), PTEN (3), MLH1 (3), SDHB (2), MSH6 (1), NF1 (1), EXT2 (1), NF1 (1), NTRK1 (1), MYH7 (3), MYL2 (1), TNNT2 (1), LDLR (2), FBN1 (1), and KCNH2 (1) were recognized in 36 patients (1.5%). Twenty-eight (77.8%) patients underwent genetic counseling and received their SF results. Eighteen (64.3%) patients underwent clinical management for SFs. Genetic validation tests were administered significantly more frequently to patients with than without a SF-related personal history (P = 0.025). This was a first attempt at a large-scale systematic exome analysis in Japan; nevertheless, many cancer patients opted for disclosure of SFs and accepted or considered clinical management.This publication has 40 references indexed in Scilit:
- Assessment of incidental findings in 232 whole-exome sequences from the Baylor–Hopkins Center for Mendelian GenomicsGenetics in Medicine, 2015
- Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencingGenetics in Medicine, 2014
- Implementation of individualized medicine for cancer patients by multiomics-based analyses—the Project HOPE— Biomedical Research, 2014
- Prevalence and differentiation of hereditary breast and ovarian cancers in JapanBreast Cancer, 2013
- ClinVar: public archive of relationships among sequence variation and human phenotypeNucleic Acids Research, 2013
- Recommendations for returning genomic incidental findings? We need to talk!Genetics in Medicine, 2013
- ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingGenetics in Medicine, 2013
- Secondary Variants in Individuals Undergoing Exome Sequencing: Screening of 572 Individuals Identifies High-Penetrance Mutations in Cancer-Susceptibility GenesAmerican Journal of Human Genetics, 2012
- A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEffFly, 2012
- Mechanism of carcinogenesis in familial tumorsInternational Journal of Clinical Oncology, 2004